Get the Stockscreener App
2.07
3.50%
0.07
After Hours:
2.10
0.03
+1.45%
Bioatla Inc stock is traded at $2.07, with a volume of 459.93K.
It is up +3.50% in the last 24 hours and down -5.91% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$2.00
Open:
$1.98
24h Volume:
459.93K
Relative Volume:
0.41
Market Cap:
$100.05M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.7964
EPS:
-2.5993
Net Cash Flow:
$-104.11M
1W Performance:
+2.99%
1M Performance:
-5.91%
6M Performance:
-36.31%
1Y Performance:
+11.89%
1-Day Range:
$1.95
$2.095
1-Week Range:
$1.92
$2.15
52-Week Range:
$1.14
$4.02
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024 - The Manila Times
BioAtla, Inc. (NASDAQ:BCAB) has caught the attention of institutional investors who hold a sizeable 39% stake - Yahoo Finance UK
BioAtla, Inc. (NASDAQ:BCAB) Short Interest Update - MarketBeat
BioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading Into 2025 - Insider Monkey
You might want to take a look at BioAtla Inc (BCAB) now - SETE News
BioAtla Inc (BCAB) stock: A year of ups and downs - US Post News
Market Insights: BioAtla Inc (BCAB)’s Notable Gain of 7.25, Closing at 2.07 - The Dwinnex
636,136 Shares in BioAtla, Inc. (NASDAQ:BCAB) Acquired by AQR Capital Management LLC - Defense World
AQR Capital Management LLC Makes New Investment in BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
There is no doubt that BioAtla Inc (BCAB) ticks all the boxes. - SETE News
Bank of Montreal Can Buys 143,521 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy - Seeking Alpha
Renaissance Technologies LLC Sells 370,800 Shares of BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
BioAtla: Numerous Catalysts Coming In Q4 (NASDAQ:BCAB) - Seeking Alpha
Analyzing the Impact of Earnings Reports on BioAtla Inc Inc. (BCAB) Price Performance - The InvestChronicle
BioAtla to Score Up to $133M - San Diego Business Journal
Should investors be concerned about BioAtla Inc (BCAB)? - US Post News
BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024 - Quantisnow
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting - ForexTV.com
Pleasing Signs As A Number Of Insiders Buy BioAtla Stock - Simply Wall St
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
JMP Securities gives a Mkt outperform recommendation for BioAtla Inc (BCAB) - Knox Daily
Rhumbline Advisers Cuts Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Potential Price Increase for Equinix Inc (EQIX) After Recent Insider Activity - Knox Daily
BCAB’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Analyzing BCAB’s price-to-book ratio for the last quarter - US Post News
Michael Burry buys 634,000 shares of this $1 penny stockFinbold - Finbold - Finance in Bold
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress - The Manila Times
BioAtla Inc (BCAB)’s financial ratios: A comprehensive overview - The Dwinnex
A new trading data show BioAtla Inc (BCAB) is showing positive returns. - SETE News
XTX Topco Ltd Trims Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Michael Burry just bought 633,959 shares in this $1 penny stock - Motley Fool UK
Scion Asset Management LLC Purchases Shares of 633,959 BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Wall Street SWOT: BioAtla stockInnovative cancer therapy faces pivotal year - Investing.com
BCAB’s valuation metrics: A comprehensive analysis - US Post News
Scion Asset Management LLC Purchases New Holdings in BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
Century Therapeutics (NASDAQ:IPSC) & BioAtla (NASDAQ:BCAB) Financial Comparison - Defense World
BioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment Development - MSN
BioAtla - The Pharma Letter
Analyzing Bio-Techne Corp (TECH) After Recent Trading Activity - Knox Daily
BlackRock Capital Allocation Term Trust (NYSE:BCAT) Major Shareholder Saba Capital Management, L.P. Sells 33,209 Shares - Defense World
BioAtla out-licenses T cell therapy in $134 million deal - The Pharma Letter
(BTMD) Technical Pivots with Risk Controls - Stock Traders Daily
BioAtla licenses cancer drug candidate to Context Therapeutics By Investing.com - Investing.com Canada
BioAtla licenses cancer drug candidate to Context Therapeutics - Investing.com
Ventyx deal a sign of Sanofi’s growing interest neuro-immunology? - BioCentury
Dawson James downgrades BioCardia Inc. (BCDA) stock to a Neutral - Knox Daily
Context Therapeutics signs second multimillion-dollar licensing deal in 3 months - The Business Journals
BlackRock Capital Allocation Term Trust (NYSE:BCAT) Major Shareholder Sells $245,706.93 in Stock - Defense World
SickKids names FCB Canada new AOR - Strategy Online
Context builds up bank of bispecific antibodies with up to $133M biobucks deal for BioAtla asset - Fierce Biotech
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bioatla Inc Stock (BCAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SHORT JAY M PHD | Chief Executive Officer |
Dec 20 '23 |
Buy |
2.14 |
50,000 |
106,910 |
1,439,283 |
| STEINMAN LAWRENCE | Director |
Dec 19 '23 |
Buy |
2.05 |
20,000 |
41,048 |
38,459 |
| Vasquez Christian | See Remarks |
Dec 19 '23 |
Buy |
2.04 |
7,495 |
15,262 |
115,659 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):